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 In this work we present evidence that A769662, a novel activator of AMP-activated 
protein kinase (AMPK), is able to inhibit the function of the 26S proteasome by an AMPK-
independent mechanism. Contrary to the mechanism of action of most proteasome inhibitors, 
A769662 does not affect the proteolytic activities of the 20S core subunit, defining in this way 
a novel mechanism of inhibition of 26S proteasome activity. Inhibition of proteasome activity 
by A769662 is reversible and leads to an arrest of cell cycle progression. These side effects of 
this new activator of AMPK should be taken into account when this compound is used as an 






Proteasomes are one of the major pathways of intracellular protein degradation in 
mammalian cells ([1], [2], [3], [4]). Although proteasomes can degrade proteins by ubiquitin-
independent processes, they are mostly involved in the ATP- and ubiquitin-dependent 
pathway of protein degradation [5]. The 26S proteasome itself is also an ATP-dependent 
complex. This complex consists of the 20S catalytic core, where the proteins are degraded, 
plus one or two 19S regulatory complexes. The 19S complex is composed of at least 19 
different subunits that form a lid- and a base-like structure; the lid provides the binding sites 
for poly-ubiquitinated substrates and a deubiquitinating activity involved in recycling of 
ubiquitin moieties upon substrate degradation; the base includes six ATPases that interact with 
the 20S proteolytic core; these ATPases have chaperone function and are required for the 
unfolding of substrates and their translocation to the 20S proteolytic chamber ([6], [7], [8]). 
Therefore, intracellular protein degradation by the proteasome is a highly energy-demanding 
process and, thus, it is expected that under conditions of energy depletion this process should 
be tightly regulated. 
AMP-activated protein kinase (AMPK) is a conserved sensor of cellular energy. 
AMPK is a heterotrimer composed of three different subunits, i.e. ,  and . AMPK is the 
catalytic subunit, whereas AMPK and AMPK play regulatory roles (see [9], for review). 
Activity of AMPK complex is regulated by the phosphorylation of the catalytic -subunit at 
Thr172 by an upstream kinase, sharing LKB1 and CaMKK this role (see [9], for review). 
The activated kinase switches on ATP-generating catabolic pathways while turning off many 
ATP-requiring processes. Since AMPK is a sensor of cellular energy, it seems plausible that 
AMPK plays a role in the regulation of proteasomal protein degradation. In fact, we have 
recently described that AMPK activation (produced by AICAR or metformin) results in an 
inhibition of proteasomal activity [10]. Since AICAR has side effects in cell metabolism that 
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are not related to AMPK activation, we decided to confirm our results by the use of the 
A769662 compound, a novel activator of AMPK ([11], [12], [13]). 
 In this work we describe that A769662 is an inhibitor of proteasomal function that acts 
by an AMPK-independent mechanism. Inhibition of proteasome activity by A769662 is 
reversible and leads to an arrest of cell cycle progression. To our knowledge, this is the first 
time that side effects of this compound are described and they should be taken into account 
when this compound is used as an alternative activator of AMPK. 
 
MATERIALS AND METHODS 
Materials 
 A769662 was kindly provided by Dr. Kei Sakamoto (MRC Protein Phosphorylation 
Unit, College of Life Sciences, University of Dundee) and dissolved in DMSO. Lactacystin 
and epoxomicin were from Biomol Research Labs (Exeter, UK). AMPK subunit double 
knockout mouse embryonic fibroblasts (MEFs) (1-/- and 2-/-) and wild type controls were 
grown as described previously [14]. HEK-GFPu-1 cells [15] were from the American Type 
Culture Collection.  
 
In vivo determination of proteasome activity. 
 Wild type and AMPK subunit double knockout (1-/- and 2-/-) MEFs (35,000 
cells) were grown in complete DMEM medium (Lonza Bioscience, Barcelona). Then, they 
were incubated for 1h in Krebs-Henseleit (KH) medium [10], containing lactacystin (10 M), 
different amounts of A769662 (from 10 to 300 M) or the corresponding vehicle (DMSO). 
Finally, the chymotrypsin-like activity of the 26S proteasome was measured using the 
Proteasome-Glo Cell-Based Assay with N-Suc-LLVY-aminoluciferin as substrate (Promega, 
Madison, WI), following the manufacturer’s instructions. Luminiscence was measured in a 
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Spectra Max M5 microplate reader (Molecular Devices, Sunnyvale, CA). Results were 
referred to the activity found in wild type MEFs cells growing in KH medium with DMSO. 
 HEK-GFPu-1 cells were cultured in DMEM medium and then incubated for 1h in KH 
medium containing lactacystin (10 M), different amounts of A769662 (50 M or 300 M) or 
the corresponding vehicle (DMSO). Fluorescence was determined by flow cytometry using a 
FACScanto flow cytometer (Becton Dickinson) using an excitation laser at 488 nm and GFP 
fluorescence detection at 520 nm. 
 
In vitro determination of proteasome activity 
 To measure the in vitro activity of the 26S proteasome we used a commercial 26S 
proteasome preparation (from human erythrocytes; Biomol Research Labs; Exeter, UK) 
combined with a fluorescent detection procedure (based on the degradation of FITC-casein) 
from Sigma (St. Louis, Mo), as described in [16]. The in vitro activity of the 20S proteasome 
was measured using the commercial 20S Proteasome Assay Kit from Biomol Research Labs 
(Exeter, UK) containing a purified preparation of the 20S proteasome from human 
erythrocytes and Suc-LLVY-AMC as substrate. The in vitro effect of A769662 on both 
proteasome preparations was analyzed following the corresponding manufacturer’s 
instructions. Fluorescence at 535 nm (excitation at 485 nm) in the case of the 26S proteasome 
reaction, and at 460 nm (excitation at 360 nm) in the case of the 20S proteasome reaction, was 
recorded in a Spectra Max M5 microplate reader (Molecular Devices, Sunnyvale, CA). 
 In-gel peptidase overlay assays with purified 26S and 20S proteasomes were carried 
out using native gel electrophoresis and Suc-LLVY-AMC as substrate as in [17]. Three g of 
commercial purified 26S and 20S proteasomes (see above) were used in these assays. After 




 Cell lysates were prepared as described in [10]. Sixty g of total protein from cell 
lysates were analyzed by SDS-PAGE and western blotting using anti-ubiquitin, anti-S1 (19S 
regulatory particle) or anti-2 (20S proteasome) antibodies (Biomol Research Labs; Exeter, 
UK). 
 
Flow cytometry and microscopic analysis 
 Cell viability of MEF cells treated or not with A769662 was performed as follows: 
cells were harvested by trypsinization and incubated with 0.5 mg/ml RNase and 50 μg/ml 
propidium iodine at room temperature in the dark; cell viability was analyzed by flow 
cytometry using a FACScanto flow cytometer (Becton Dickinson), using an excitation laser at 
488 nm and a propidium iodine fluorescence detection at 600 nm. To determine the proportion 
of cells in each phase of the cell cycle, cells were harvested by trypsinization, collected by 
centrifugation, washed in PBS and fixed overnight in 80% ethanol at -20ºC. Subsequently 
these fixed cells were centrifuged to remove the fixative and incubated for 20 min in the dark 
at room temperature in PBS containing 0.5 mg/ml RNase and 50 μg/ml propidium iodine. 
Flow cytometry analysis was performed as above. The proportion of cells in G1, S, and G2 
was determined using the MODFIT program. 
 Cell culture pictures were taken at the indicated times using a camera (Olympus 
Camedia C-5060 wide zoom) coupled to an inverted microscope (Zeiss Axiovert 40C) with a 
20X objective. 
 
Statistical data analysis. 
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Data are expressed as mean values ± standard error (SE). Statistical significance of 
differences between the groups was evaluated by a paired Student’s t test with two-tailed 
distribution. The significance has been considered at ** p<0.01 or *** p<0.001, as indicated. 
 
 
RESULTS AND DISCUSSION 
1.- A769662 inhibits proteasomal activity by an AMPK-independent mechanism. 
 We have recently described that activation of AMPK, either by AICAR or by 
metformin, affects negatively proteasomal function [10]. To confirm these results we have 
used a novel activator of AMPK named A769662 (see Introduction). In agreement with 
previous results, treatment of wild type mouse embryonic fibroblast (MEF) cells with 
A769662 resulted in an increase in the phosphorylation of the AMPK catalytic subunit at 
Thr172 residue (data not shown). This new compound was also able to inhibit in vivo the 
proteasomal function in MEF cells, with an IC50 of 62 M (Fig. 1A). However, the 
compound was also able to inhibit in vivo the proteasomal function in AMPK subunit double 
knock-out (1-/-, 2-/-) MEFs, with similar IC50 (47 M; no statistically significant 
differences were found respect to wild type MEFs), indicating that A769662 was able to 
inhibit proteasomal function in an AMPK-independent manner (Fig. 1A). A769662 was not as 
potent as other already known proteasomal inhibitors such as lactacystin, which has an IC50 
in the nanomolar range [18]; in fact, 10 M of lactacystin was able to inhibit almost 
completely proteasomal function (Fig. 1). 
 We then confirmed that A769662 was an inhibitor of proteasomal function by 
alternative methods. As it is shown in Fig. 1B, MEF cells treated with 300 M A769662 for 
1h were able to accumulate poly-ubiquitinated proteins, an indication of proteasomal 
impairment, as in the case of cells treated with the proteasomal inhibitor lactacystin (10 M) 
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(similar results were obtained in double 12 -/- KO MEF cells; not shown). In addition, we 
used an alternative assay based on the degradation of a fusion protein of GFP with a short 
degron (CL1) fused to the C-terminus (GFPu) [15]. This fusion protein is unstable and is 
rapidly degraded by the 26S proteasome under regular conditions. If the function of the 
proteasome is impaired, then the GFPu protein is accumulated, what leads to an increase in the 
amount of GFP-dependent fluorescence. As shown in Fig. 1C, treatment of HEK-GFPu-1 cells 
with lactacystin (10 M) resulted in an increase in the GFP-dependent fluorescence of the 
cells, assessed by flow cytometry. When the cells were treated with A769662, we also 
observed an increase in GFP-dependent fluorescence that was dose-dependent (Fig. 1C). 
 We also studied the possibility that A769662 could affect indirectly proteasome 
function, i.e. by preventing transcription or translation of proteasomal genes. However, we 
ruled out this possibility when we observed similar amounts of two characteristic endogenous 
subunits of the proteasome, such as the S1 subunit from the 19S regulatory particle and the 2 
subunit from the 20S proteasome catalytic core, in extracts from cells treated or not with 300 
M A769662 for different periods of time (Fig. 1D). 
 All these results indicated that A769662 was an inhibitor of the proteasomal function 
and that the mechanism of its inhibition was AMPK-independent. 
 
2.- Inhibition of proteasomal activity by A769662 is reversible. 
 In all our experiments we grew the cells in complete medium (DMEM) and then 
replaced this medium by a poor medium (KH) to increase intracellular protein degradation. In 
order to determine whether A769662 inhibited the activation of the proteasomal function upon 
shift from the complete to the KH medium or whether this compound was able to inhibit a 
pre-existing proteasomal activity, we subjected MEF cells to a shift from complete to KH 
medium for 1h and then, treated the cells with A769662 or with vehicle alone (DMSO). We 
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observed that A769662 was able to reduce the activity of pre-existing proteasomal activity 
(Fig. 2A), suggesting a direct effect of the compound on the proteasome. Additionally, we 
checked whether the inhibition was reversible. With this aim, we treated MEF cells with 
A769662 for 1h and then, we removed the culture medium and replaced it with fresh KH 
medium for an extra hour. As observed in Fig. 2B, a clear increase in the activity of the 
proteasome was observed upon removal of A769662, indicating a reversible mechanism of 
inhibition. 
 
3.- A769662 affects in vitro the activity of purified 26S but not the activity of 20S 
proteasomes. 
 The 26S proteasome is a high molecular weight proteolytic complex consisting of the 
20S core, where proteins are degraded, plus one or two 19S regulatory particles (RP), 
composed of six ATPases and other components necessary for binding, unfolding and 
translocation of the protein substrates into the 20S core for hydrolysis (see Introduction). In 
order to determine whether A769662 was able to inhibit in vitro the activity of either the 26S 
or the 20S proteasomes, we used commercial preparations of both complexes. As shown in 
Fig. 3A, the activity of the 26S preparation was inhibited by epoxomicin (0.5 M), a known 
proteasomal inhibitor [18]. Similarly, A769662 was also able to inhibit the activity of the 26S 
proteasomes, [values were similar to those found in the sample without 26S proteasomes 
(blank), even at low concentrations of the compound (10 M)], confirming the in vivo 
inhibition of proteasomal function described above. However, we were not able to detect any 
inhibition of the activity of the 20S proteasome preparation when we used A769662, at any of 
the tested concentrations (from 5 to 100 M) (Fig. 3B). This result could indicate that 
A769662 does not affect the proteolytic activity present in the 20S proteasome core. 
Additionally, we observed that treatment of the 26S proteasomes with A769662 did not 
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disrupt the association of the 19S regulatory particle with the 20S proteasomes (Fig. 3C). 
Therefore, we suggest that A769662 inhibits 26S proteasomes by affecting the function of the 
19S regulatory particle, preventing in this way the entry of the poly-ubiquitinated substrates 
into the 20S proteolytic chamber. 
 
4.- A769662 has toxic effects on MEF cells. 
 It has been described that inhibition of the proteasome function results in cell cycle 
arrest and apoptosis, probably because of the accumulation of pro-apoptotic proteins and the 
downregulation of anti-apoptotic factors ([8], [19]). In order to determine whether A769662 
promoted similar effects, we treated MEF cells with A769662 and determined its effects on 
cell cycle and cell viability. Microscopic analysis of cell cultures indicated that after 12 h of 
treatment, there was an increase in the amount of round cells that were not attached to the 
culture plate surface. The amount of unattached cells increased dramatically after 24 h of 
treatment (Fig. 4A). Similar results were obtained in double 12 -/- KO MEF cells (Fig. 4A) 
indicating that the effect was not due to AMPK activation. Cells were assessed for viability by 
flow cytometry and the results indicated a huge increase in the amount of non-viable cells 
after 24 hours of treatment (24.0% of non-viable cells in the samples treated with A769662 
versus 6.3% in cells treated with vehicle alone; Fig. 4B). Similar results were obtained in 
double 12 -/- KO MEF cells (not shown). These results are in contrast to those previously 
reported that indicated that A769662 showed no measurable cytotoxicity in rat hepatocytes 
[11]. Probably the different cell type may account for this difference, since several studies 
have demonstrated that proliferating cell lines are usually more sensitive to proteasome 
inhibitors than non proliferating ones ([20], [21]). Flow cytometry analysis of MEF cells 
indicated that whereas in samples treated with vehicle alone (DMSO) the proportion of cells 
in G1 increased after 24 h (with the corresponding decrease of cells in G2), samples treated 
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with A769662 did not show any significant variation in the amount of cells in G1 and G2 after 
24 h. These results are consistent with a cell cycle arrest caused by the inhibition of the 
proteasome, as the proteasome is essential for the progression through many steps in the cell 
cycle ([18], [22]). 
 In conclusion, we have demonstrated that A769662 is an inhibitor of proteasomal 
function that acts by an AMPK-independent mechanism. We have also observed toxic effects 
of this compound on MEF cells, probably as a consequence of proteasome inhibition. To our 
knowledge, this is the first time that side effects of this compound are described and they 
should be taken into account when this compound is used as an alternative activator of 
AMPK. On the other hand, inhibition of proteasomal activity by A769662 does not involve 
inhibition of the proteolytic activity of the 20S proteasome, in contrast to most proteasomal 
inhibitors. Thus, the mechanism of action of A769662 opens a new way in the development of 
novel inhibitors of proteasomal activity in the cells. 
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Fig. 1: A769662 inhibits proteasomal function by an AMPK-independent mechanism. A) 
Wild type (WT) and AMPK subunit double knockout (1-/- and 2-/-; KO) MEFs were 
cultivated in complete DMEM medium. Then, they were incubated for 1h in KH medium 
containing lactacystin (10 M), different amounts of A769662 (from 10 to 300 M) or the 
corresponding vehicle (DMSO; 0 M). The in vivo activity of the proteasome was determined 
in these cells as described in Materials and Methods. Results were referred to the activity 
found in wild type MEFs cells growing in KH medium with DMSO. B) Sixty g of total 
protein from cell lysates from treated MEF cells as above were analyzed by SDS-PAGE and 
western blotting using anti-ubiquitin antibodies; Lact: lactacystin (10 M); A769662 (300 
M). C) HEK-GFPu-1 cells were cultivated in DMEM medium and then incubated for 1h in 
KH medium containing lactacystin (Lact; 10 M), A769662 (A; 50 M or 300 M) or the 
corresponding vehicle (DMSO). Fluorescence was determined as described in Materials and 
Methods and referred to the fluorescence found in KH medium with DMSO. D) Sixty g of 
total protein from cell lysates from MEF cells treated as above with A769662 (300 M) or 
with vehicle (DMSO) for different times, as indicated, were analyzed by SDS-PAGE and 
western blotting using anti-S1 (19S regulatory particle) or anti-2 (20S proteasomes) 
antibodies. Bars indicate standard error (SE). 
 
Fig. 2: Inhibition of proteasomal activity by A769662 is reversible. A) Wild type MEF cells 
were grown in complete DMEM medium and then incubated for 1h in KH medium. Then the 
cells were treated with 50 M A769662 or with DMSO in KH for an extra hour. The in vivo 
proteasomal activity was measured as described in Materials and Methods. B) Wild type MEF 
cells were grown in complete DMEM medium and then incubated for 1h in KH medium 
containing or not 50 M A769662; then, the media were removed, replaced by fresh KH 
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medium and the cells were incubated for an extra hour. The in vivo proteasomal activity was 
measured as above. In A) and B), results are referred to the activity measured in the cells 
incubated for 1h in KH medium without A769662; bars indicate standard error (SE) and 
asterisks indicate differences which were found to be statistically significant at p<0.01 (n: 4). 
 
Fig. 3: A769662 affects the in vitro activity of purified 26S proteasomes but not the in vitro 
activity of purified 20S proteasomes. Commercial purified preparations of the 26S proteasome 
(A) and the 20S proteasomes (B) were incubated or not with 0.5 M epoxomicin (Epox) or 
the indicated concentrations of A769662. The activity of the mixtures was assayed as 
described in Materials and Methods. Blank: sample containing no 26S proteasome; in B), the 
activity was referred to the proteasome activity found in the control. Bars indicate standard 
error (SE) and asterisks indicate differences which were found to be statistically significant at 
p<0.001 (n: 4). C) In-gel peptidase overlay assays of proteasomes were carried out using Suc-
LLVY-AMC as substrate (see Materials and Methods). Three g of commercial purified 26S 
proteasomes were treated with 100 M A769662 or vehicle (DMSO) for 30 min at 37ºC. 
Three g of commercial purified 20S proteasomes were included as control (left panel). After 
visualization of the reaction, the gel was stained with cCoomassie blue (right panel). 
 
Fig. 4: A769662 has toxic effects on MEF cells. A) Cultured MEF cells from wild type and 
double 1-/- 2-/- KO mice were incubated at the indicated times in KH medium containing 
300 M A769662 or the corresponding vehicle (DMSO). B) Cell viability of wild type MEF 
cells was determined after 24 h of incubation in KH medium containing DMSO or 300 M 
A769662, as described in Materials and Methods. C) The percentage of wild type MEF cells 
in each phase of the cell cycle in cultures incubated in the presence of DMSO (white bars) or 
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in the presence of 300 M A769662 (grey bars), was determined at the indicated times, as 
described in Materials and Methods. Error bars indicate standard error (SE). 
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